首页 › 基金 › SUPERSTRING CAPITAL MANAGEMENT LP › SGMT

SUPERSTRING CAPITAL MANAGEMENT LP 对 SGMT 的持仓历史

SAGIMET BIOSCIENCES INC · 医疗保健

SUPERSTRING CAPITAL MANAGEMENT LP 在 Q3 2026 的 13F 申报中披露持有 SGMT(SAGIMET BIOSCIENCES INC)423,006 股,市值约 US$4.2M,约占其申报组合的 2.09%,在其申报持仓中市值排名第 19 位。 SUPERSTRING CAPITAL MANAGEMENT LP 于 Q3 2026 首次申报该持仓。

最新持仓 (Q3 2026)423.01K 股
申报持仓市值$4.18M
组合权重2.09%
首次申报Q3 2026
最近变动新进
更新于2026-11-16

最后更新: 2026-11-16 · 来源: SEC EDGAR Form 13F-HR

SUPERSTRING CAPITAL MANAGEMENT LP 对 SGMT 的持仓演变

SUPERSTRING CAPITAL MANAGEMENT LP 于 Q3 2026 首次披露 SGMT 持仓:423,006 股(约 US$4.2M)。

逐季持仓明细

季度股数金额变化
Q3 2026 423.01K $4.18M 新进

关于 SGMT 与 13F 数据

SGMT(SAGIMET BIOSCIENCES INC)属于医疗保健行业。我们追踪的基金中还有 61 只申报持有 SGMT,申报仓位最大的包括:SILVERARC CAPITAL MANAGEMENT, LLC (US$37.0M), Affinity Asset Advisors, LLC (US$25.0M), Saturn V Capital Management LP (US$19.8M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。

其它持有 SGMT 的基金

查看 SGMT 的全部基金持有人 →

常见问题

How long has SUPERSTRING CAPITAL MANAGEMENT LP held SGMT?

SUPERSTRING CAPITAL MANAGEMENT LP has disclosed SGMT holdings in 1 of the last 1 reported quarters, going back to Q3 2026.

What is SUPERSTRING CAPITAL MANAGEMENT LP's current position in SGMT?

As of Q3 2026, SUPERSTRING CAPITAL MANAGEMENT LP holds 423.01K shares of SGMT (SAGIMET BIOSCIENCES INC), valued at $4.18M, representing 2.09% of its reported portfolio and ranking #19.

Has SUPERSTRING CAPITAL MANAGEMENT LP been buying or selling SGMT?

In the latest 13F filing (Q3 2026), SUPERSTRING CAPITAL MANAGEMENT LP newly opened its position in SGMT.

Which other funds hold SGMT?

Other major institutional holders of SGMT include SILVERARC CAPITAL MANAGEMENT, LLC, Affinity Asset Advisors, LLC, Saturn V Capital Management LP, among 61 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.